Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

Clinical Trial ID NCT00541086

Rank	Title	Journal	Year	PubWeight™‹?›
1	Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.	J Clin Oncol	2011	2.71
2	Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.	Breast Cancer (Auckl)	2011	0.83
3	A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.	Breast Cancer Res Treat	2013	0.78